# Case Report: Successful Treatment of Dermatomyositis With Telitacicept

**Authors:** Xinyu Fu, Miao Yan, Yuan Song, Wei Liang

PMC · DOI: 10.1155/carm/2621540 · Case Reports in Medicine · 2025-10-13

## TL;DR

A 65-year-old man with dermatomyositis showed significant improvement after being treated with telitacicept, suggesting it could be an effective treatment.

## Contribution

This is the first reported case showing telitacicept's effectiveness in treating dermatomyositis.

## Key findings

- The patient showed significant clinical remission after treatment with telitacicept.
- Methylprednisolone dosage was successfully reduced following telitacicept injections.
- After one year of follow-up, the patient's symptoms were dramatically improved.

## Abstract

Dermatomyositis is an autoimmune disease. Common treatment with glucocorticoids, immunoglobulins, methotrexate, and rituximab is recommended. Telitacicept is an immunosuppressant that has been approved for the treatment of systemic lupus erythematosus in recent years. Considering the mechanism of action of telitacicept and the pathogenesis of dermatomyositis, it is rational to suppose that telitacicept may be useful in treating dermatomyositis. Here, we describe a case of a 65-year-old male patient with erythema on the face and neck, limb weakness, and edema in both upper and lower limbs. After conventional treatment therapy plus telitacicept, the patient showed significant clinical remission during the maintenance treatment. Methylprednisolone was successfully reduced after injections of telitacicept. After 1 year of follow-up, the patient's clinical symptoms were improved dramatically. This is the first report indicating that telitacicept is effective for dermatomyositis and it deserves attention.

## Linked entities

- **Chemicals:** methylprednisolone (PubChem CID 6741)
- **Diseases:** dermatomyositis (MONDO:0016367), systemic lupus erythematosus (MONDO:0007915)

## Full-text entities

- **Diseases:** autoimmune disease (MESH:D001327), systemic lupus erythematosus (MESH:D008180), Dermatomyositis (MESH:D003882), edema (MESH:D004487), weakness (MESH:D018908), neck (MESH:D006258), erythema on the face (MESH:D004890)
- **Chemicals:** Methylprednisolone (MESH:D008775), methotrexate (MESH:D008727), rituximab (MESH:D000069283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12537185/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12537185/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12537185/full.md

---
Source: https://tomesphere.com/paper/PMC12537185